Broker recommendations for Takeda Pharmaceutical Co., Ltd
The Takeda Pharmaceutical Co., Ltd stock is rated at 1.192308 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Thursday 2 July, 2020 by a total of 13 brokers. This means that the consensus of the 13 different brokers is leaning toward to buy/moderate buy.
Sell
0 (0%) Underweight
0 (0%) Hold
2 (15.38%) Overweight
1 (7.69%) Buy
10 (76.92%)
Price target by analysts
The 13 latest analyst estimates, per Monday 3 August, 2020, show the following high, low and average price targets.
Target Average: 24.86 USD
Target High: 30.63 USD
Target Low: 19.32 USD
AbbVie, Amgen and Takeda start testing drugs as COVID-19 treatments
Monday, 3 August 2020, 13:56:29
AbbVie Inc. undefined, Amgen Inc. undefined, and Takeda Pharmaceutical Co. Ltd. undefined announced they started enrolling patients in a clinical trial…
— MarketWatch
Members Of The COVID R&D Alliance And Quantum Leap Healthcare Collaborative Enroll First Patients In I-SPY COVID Trial
Monday, 3 August 2020, 13:30:00
SAN FRANCISCO, Aug. 3, 2020 /PRNewswire/ — Today, members of the COVID R&D Alliance AbbVie, Inc. (NYSE: ABBV), Amgen Inc. (NASDAQ: AMGN), and Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) announced the first patients enrolled in the I-SPY COVID Trial (Investigation of Serial Studies to…
— PR Newswire
Global Hypoparathyroidism Pipeline Monitor 2020 with Analysis of 11 Companies Including Ascendis Pharma, Eli Lilly & Co and Takeda Pharma – ResearchAndMarkets.com
Monday, 3 August 2020, 12:50:00
DUBLIN–(BUSINESS WIRE)–The “Hypoparathyroidism Pipeline Research Monitor, 2020 – Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook” report has been added to ResearchAndMarkets.com’s offering. PIPELINE HIGHLIGHTS Hypoparathyroidism is one of the widely researched conditions during 2020 with 11 companies actively focusing on realizing pipeline’s potential. Development of Hypoparathyroidism medicines is identified as integral to the strategy of the majority of compa
— Business Wire
Takeda Pharmaceutical : Announcement of a merger (simple merger/short-form merger) with a wholly owned subsidiary | MarketScreener
Monday, 3 August 2020, 08:13:20
Osaka, Japan, August 3, 2020 — Takeda Pharmaceutical Company Limited , ‘Takeda’) decided today to perform an absorption-type merger of Shire Japan KK, which is Takeda’s… | August 3, 2020
— MarketScreener
Takeda Announces FY2020 Q1 Results; Confirms Management Guidance & Raises Reported Operating Profit And Reported Net Profit for the Full Year
Friday, 31 July 2020, 09:55:00
OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the first quarter of fiscal year 2020 (quarter ended June 30, 2020). Based on the first quarter performance, the company confirms management guidance, and raises reported operating profit and reported net profit for the full year. The company also announced recent updates to its R&D pipeline and highlighted its R&D momentum with seven potential New
— Business Wire
